|
| Status |
Public on May 07, 2019 |
| Title |
Gene expression profiles in CYP2C19-deficient human iPS cell-derived hepatocyte-like cells |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Cytochrome P450 family 2 subfamily C member 19 (CYP2C19), in liver, plays important roles in terms of drug metabolism. It is known that CYP2C19 poor metabolizers (PMs) lack CYP2C19 metabolic capacity. Thus, unexpected drug-induced liver injury or decrease of drug efficacy would be caused in CYP2C19 substrate-treated CYP2C19 PMs. However, it is difficult to evaluate the safety and effectiveness of drugs and candidate compounds for CYP2C19 PMs because there is currently no model for this phenotype. Here, using human iPS cells and our highly efficient genome editing and hepatocyte differentiation technologies, we generated CYP2C19-knockout human iPS cell-derived hepatocyte-like cells (CYP2C19-KO HLCs) as a novel CYP2C19 PM model for drug development and research. The gene expression levels of hepatocyte markers were similar between WT HLCs and CYP2C19-KO HLCs, suggesting that CYP2C19 deficiency did not affect the hepatic differentiation potency. We also examined CYP2C19 metabolic activity by measuring S-mephenytoin metabolites using LC-MS. The CYP2C19 metabolic activity was almost eliminated by CYP2C19 knockout. Additionally, we evaluated whether clopidogrel (CYP2C19 substrate)-induced liver toxicity could be predicted using our model. Unexpectedly, there was no significant difference in cell viability between clopidogrel-treated WT HLCs and CYP2C19-KO HLCs. However, the cell viability in clopidogrel- and ketoconazole (CYP3A4 inhibitor)-treated CYP2C19-KO HLCs was significantly enhanced as compared with that in clopidogrel- and DMSO-treated CYP2C19-KO HLCs. This result suggests that CYP2C19-KO HLCs can predict the clopidogrel-induced liver toxicity. We succeeded in generating CYP2C19 PM model cells using human iPS cells and genome editing technologies for pharmaceutical research.
|
| |
|
| Overall design |
We generated CYP2C19-deficient human iPS cells based on a human iPS cell line, FCL-iPS (Takayama et al., 2014). Each CYP2C19-deficient iPS cells and wild type iPS cells were differentiated into hepatocyte-like cells (CYP2C19-KO HLCs and WT HLCs, respectively). CYP2C19-KO HLCs and WT HLCs were pooled from triplicate samples of one independent experiments, and then microarray analysis was performed.
|
| Web link |
http://dmd.aspetjournals.org/content/early/2019/04/08/dmd.119.086322.1.long
|
| |
|
| Contributor(s) |
Deguchi S, Yamashita T, Igai K, Harada K, Toba Y, Hirata K, Takayama K, Mizuguchi H |
| Citation(s) |
30962288 |
| |
| Submission date |
Dec 17, 2018 |
| Last update date |
May 09, 2019 |
| Contact name |
Tomoki Yamashita |
| E-mail(s) |
yamashita-t@phs.osaka-u.ac.jp
|
| Organization name |
Osaka University
|
| Department |
Graduate School of Pharmaceutical Sciences
|
| Lab |
Laboratory of Biochemistry and Molecular Biology
|
| Street address |
1-6 Yamadaoka
|
| City |
Suita |
| State/province |
Osaka |
| ZIP/Postal code |
5650871 |
| Country |
Japan |
| |
|
| Platforms (1) |
| GPL20844 |
Agilent-072363 SurePrint G3 Human GE v3 8x60K Microarray 039494 [Feature Number Version] |
|
| Samples (2) |
|
| Relations |
| BioProject |
PRJNA510356 |
